Director/PDMR Shareholding

15 July 2014

Synergy Health plc ("Synergy", the "Company", or the "Group")

Director/PDMR Shareholding

The Company announces the following transactions by a person discharging managerial responsibilities ("PDMR"), in Synergy Health plc ordinary shares of 0.625 pence each ("Ordinary Shares") and the consequent allocations of Ordinary Shares to the LTIP Co-Invest scheme:

1) Mr Gavin Hill, Group Finance Director, exercised options over 12,145 Ordinary Shares under the Company's LTIP scheme. 5,741 Ordinary Shares were sold at 1,379 pence per share. 6,404 Ordinary Shares have been retained by Mr Hill and allocated to the LTIP Co-Invest Scheme. As a result of the allocation to the Company's Co-Invest Scheme, Mr Hill has been granted an LTIP Co-Invest option of 12,808 options. Following the transaction Mr Hill has an interest in 39,884 Ordinary Shares, representing 0.07% of the Company's issued share capital.

2) Dr Adrian Coward, Chief Operating Officer, exercised options over 6,705 Ordinary Shares under the Company's LTIP scheme. These Ordinary Shares have been retained by Dr Coward and allocated to the LTIP Co-Invest Scheme. As a result of the allocation to the Company's Co-Invest Scheme, Dr Coward has been granted an LTIP Co-Invest option of 13,410 options. Following the transaction Dr Coward has an interest in 38,003 Ordinary Shares, representing 0.06% of the Company's issued share capital.

3) Mr Tim Mason, Group Company Secretary, exercised options over 5,672 Ordinary Shares under the Company's LTIP scheme. 2,681 Ordinary Shares were sold at 1,361 pence per share. 2,991 Ordinary Shares have been retained by Mr Mason. Following the transaction Mr Mason has an interest in 14,421 Ordinary Shares, representing 0.02% of the Company's issued share capital.

4) Mr Andrew Mclean, CEO AST and Laboratories, purchased 1,270 Ordinary Shares at a price range of between 1,380 pence and 1,385 pence on 14 July 2014 and allocated these shares to the LTIP Co-Invest scheme. Following the transaction Mr Mclean has an interest in 7,656 Ordinary Shares, representing 0.01% of the Company's issued share capital. As a result of the above allocation to the Company's Co-Invest Scheme, Mr Mclean has been granted an additional LTIP Co-Invest option of 2,540 options.

The LTIP Co-Invest arrangement requires that the participant to whom the award is to be made invests in Ordinary Shares in the Company and continues to hold those Ordinary Shares throughout the three year measurement period. At the end of the measurement period, depending upon the growth in earnings per share of the Company over the measurement period, the participant will receive a number of "matching" shares at nominal value under the LTIP Co-Invest.

For further information:

Tim Mason, Group Company Secretary +44 (0) 1793 891 862